From: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
Variables | miR-10a-5p expression | TFAP2C expression | ||||
---|---|---|---|---|---|---|
Low group | High group | P value | Low group | High group | P value | |
(n = 35) | (n = 55) | (n = 44) | (n = 46) | |||
Gender | Â | Â | 0.270 | Â | Â | 0.670 |
 Male | 24 | 30 |  | 28 | 27 |  |
 Female | 11 | 25 |  | 16 | 19 |  |
Age(years old) | Â | Â | 0.380 | Â | Â | 0.831 |
 <65 | 23 | 30 |  | 25 | 28 |  |
  ≥ 65 | 12 | 25 |  | 19 | 18 |  |
Locations | Â | Â | 0.532 | Â | Â | 0.372 |
 Head | 23 | 37 |  | 27 | 33 |  |
 Body-tail | 12 | 18 |  | 17 | 13 |  |
Perineuronal invasion | Â | Â | 1.000 | Â | Â | 0.019 |
 No | 20 | 31 |  | 19 | 32 |  |
 Yes | 15 | 24 |  | 25 | 14 |  |
Tumor staging | Â | Â | 0.790 | Â | Â | 0.426 |
 T1/T2 | 29 | 44 |  | 34 | 39 |  |
 T3/T4 | 6 | 11 |  | 10 | 7 |  |
Lymph node staging | Â | Â | 0.519 | Â | Â | 0.832 |
 N0 | 23 | 31 |  | 27 | 27 |  |
 N1 | 12 | 24 |  | 17 | 19 |  |
TNM staging | Â | Â | 0.084 | Â | Â | 0.505 |
 I | 21 | 22 |  | 22 | 21 |  |
 II | 14 | 33 |  | 22 | 25 |  |
Diabetes | Â | Â | 0.399 | Â | Â | 0.169 |
 No | 27 | 47 |  | 39 | 35 |  |
 Yes | 8 | 8 |  | 5 | 11 |  |